What is FDA Category 1 for peptides?

FDA Category 1 is a classification on the 503A Bulk Drug Substances List — the list of bulk substances that registered 503A compounding pharmacies can legally use. A peptide on Category 1 can be compounded by licensed 503A pharmacies and dispensed to patients with a valid prescription from a licensed provider. It does NOT mean the peptide is FDA-approved as a drug; it means a licensed pharmacy can compound it for a patient.

Which peptides are in the 2026 FDA compounding review?

In April 2026 the FDA removed 12 peptides from Category 2 (the significant-safety-risk list): BPC-157, GHK-Cu, CJC-1295, Ipamorelin, Thymosin Beta-4 (TB-500), Tesamorelin, Sermorelin, GHRP-2, GHRP-6, DSIP, Selank, and GHK. Removal from Category 2 does NOT place them on the Category 1 (503A) list or authorize compounding — they sit in a regulatory gray zone. The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review nominations and make recommendations; the FDA issues any final rule later.

What is the FDA PCAC meeting on July 23–24, 2026?

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is an advisory committee that meets July 23–24, 2026 to review nominations for the 503A Bulk Drug Substances List. The committee reviews the scientific evidence for each nominee and makes recommendations to the FDA on whether each substance is appropriate for 503A compounding — it does not make the final decision. The FDA issues any final rule later, typically months after the meeting.

Will I need a prescription to get Category 1 peptides?

Yes. A valid prescription from a licensed healthcare provider is required to obtain compounded peptides from a 503A pharmacy. If and when peptides are officially added to the Category 1 (503A) list, the appropriate route would be through a licensed compounding pharmacy with a prescriber's order. Research vendors selling peptides labeled 'for research use only' operate under a different framework and are not licensed to dispense medications.

Can I still buy BPC-157, CJC-1295, or TB-500 from research vendors in 2026?

Research peptide vendors sell compounds labeled 'for research use only' under a different regulatory framework from pharmaceutical compounding. If and when the FDA finalizes any changes to the 503A Bulk Drug Substances List, the regulatory landscape for research vendors may change, but Disclosed Labs does not provide legal or regulatory compliance advice. Consult a regulatory attorney or licensed pharmacist for guidance on how any FDA rule change affects the research market.

How do I find a prescriber for compounded peptides?

Disclosed Labs maintains a directory of NPI-verified providers at disclosedlabs.com/prescribers, including telehealth practices that prescribe compounded peptides to patients in multiple states. A telehealth consultation can result in a prescription that any licensed 503A compounding pharmacy can fill.

FDA advisory meeting: July 23–24, 2026 — FDA PCAC reviews nominations and makes recommendations; the FDA issues any final rule later.

FDA Category 1 Peptides 2026:
What the Reclassification Means

In April 2026, the FDA removed 12 peptides from Category 2 (the significant-safety-risk list) — placing them in a regulatory gray zone. Removal from Category 2 does not authorize compounding or place these peptides on the Category 1 (503A) list. The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review nominations and make recommendations — the FDA issues any final rule later. Here's what it means and what to expect.

What is FDA Category 1?

Category 1 — Compoundable

The FDA has determined the substance is appropriate for compounding by registered 503A pharmacies — with a valid prescription from a licensed provider.

Category 2 — Under review

The FDA is evaluating whether compounding is appropriate. The 12 peptides in this guide are moving out of Category 2.

Category 3 — Not eligible

The FDA has determined these substances are not appropriate for 503A compounding. Examples include some discontinued GLP-1 compounds.

Category 1 status does not mean FDA-approved as a drug — it means a licensed 503A pharmacy can produce a customized formulation for a specific patient with a valid prescription. This is the same pathway used for many common compounded medications.

Key dates

April 2026

FDA removes 12 peptides from Category 2

The FDA removed 12 peptides from Category 2 (the significant-safety-risk / cannot-compound list). Removal does NOT authorize compounding or place them on Category 1 — they enter a regulatory gray zone pending further review.

July 23–24, 2026

FDA PCAC advisory meeting

The FDA's Pharmacy Compounding Advisory Committee reviews nominations and makes recommendations on which substances belong on the 503A list. The PCAC is advisory — it does not issue a final rule. Open to the public via the FDA advisory committee calendar.

Post-meeting (months later)

Possible final rule

After reviewing PCAC recommendations, the FDA may issue a final rule updating the 503A Bulk Drug Substances List. Final rules typically take months to years after an advisory meeting. If and when a peptide is added to the Category 1 list, licensed 503A compounding pharmacies could compound it for patients with a valid prescription.

The 12 peptides in the 2026 review

All 12 were removed from Category 2 in April 2026 and are now under PCAC review — none are yet on the Category 1 (503A) authorized list. Vendor counts reflect COA-verified (Grade C+) research vendors currently tracked on Disclosed Labs.

BPC-157

Healing / Recovery

Very High demand

51 vendors Status →

GHK-Cu

Skin / Copper Peptide

High demand

50 vendors Status →

CJC-1295

Growth Hormone Secretagogue

Very High demand

31 vendors Status →

Ipamorelin

Growth Hormone Secretagogue

Very High demand

How to access Category 1 peptides legally

After the 2026 reclassification, the pathway for legally obtaining Category 1 compounded peptides is straightforward — and the same as any compounded medication:

1
Consult a licensed provider
A licensed healthcare provider — physician, nurse practitioner, or physician assistant — must evaluate your case and determine whether a compounded peptide is clinically appropriate. Many telehealth practices specialize in peptide therapy and can consult patients in multiple states.
Find a prescriber →
2
Obtain a prescription
If appropriate, the provider issues a patient-specific prescription for the peptide, formulation, strength, and route of administration. The prescription is sent directly to the compounding pharmacy.
3
Pharmacy compounds and ships
A licensed 503A compounding pharmacy prepares the peptide to USP <797> pharmaceutical standards — including identity, purity (HPLC), endotoxin, and sterility testing — and ships it to the patient.
Browse compounding pharmacies →

How compounding pharmacy quality differs from research vendors

Compounding pharmacies operating under 503A must meet USP <797> pharmaceutical manufacturing standards — including:

Identity and potency testing (HPLC/UPLC) on every batch
Endotoxin testing (LAL) — required for injectable preparations
Sterility testing (USP <71>) per compendial standards
Heavy-metals screening for parenteral preparations
State pharmacy board licensure and, for 503B facilities, FDA registration

Disclosed Labs tracks COA quality data for research vendors. Browse the COA corpus →

Frequently asked questions

What is FDA Category 1 for peptides?: FDA Category 1 is a classification on the 503A Bulk Drug Substances List — the list of bulk substances that registered 503A compounding pharmacies can legally use. A peptide on Category 1 can be compounded by licensed 503A pharmacies and dispensed to patients with a valid prescription from a licensed provider. It does NOT mean the peptide is FDA-approved as a drug; it means a licensed pharmacy can compound it for a patient.
Which peptides are in the 2026 FDA compounding review?: In April 2026 the FDA removed 12 peptides from Category 2 (the significant-safety-risk list): BPC-157, GHK-Cu, CJC-1295, Ipamorelin, Thymosin Beta-4 (TB-500), Tesamorelin, Sermorelin, GHRP-2, GHRP-6, DSIP, Selank, and GHK. Removal from Category 2 does NOT place them on the Category 1 (503A) list or authorize compounding — they sit in a regulatory gray zone. The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review nominations and make recommendations; the FDA issues any final rule later.
What is the FDA PCAC meeting on July 23–24, 2026?: The FDA's Pharmacy Compounding Advisory Committee (PCAC) is an advisory committee that meets July 23–24, 2026 to review nominations for the 503A Bulk Drug Substances List. The committee reviews the scientific evidence for each nominee and makes recommendations to the FDA on whether each substance is appropriate for 503A compounding — it does not make the final decision. The FDA issues any final rule later, typically months after the meeting.
Will I need a prescription to get Category 1 peptides?: Yes. A valid prescription from a licensed healthcare provider is required to obtain compounded peptides from a 503A pharmacy. If and when peptides are officially added to the Category 1 (503A) list, the appropriate route would be through a licensed compounding pharmacy with a prescriber's order. Research vendors selling peptides labeled 'for research use only' operate under a different framework and are not licensed to dispense medications.
Can I still buy BPC-157, CJC-1295, or TB-500 from research vendors in 2026?

Live status tracker

Per-peptide regulatory status with vendor data

Find a prescriber

NPI-verified providers who work with compounded peptides

Compounding pharmacies

Licensed 503A/503B pharmacies with quality scores

This page contains regulatory information only. Disclosed Labs does not provide legal, medical, or pharmaceutical advice. In April 2026 the FDA removed 12 peptides from Category 2; no final Category 1 rule has been issued — verify current regulatory status with the FDA or a licensed regulatory professional. For research use only.

FDA Category 1 Peptides 2026: What the Reclassification Means

What is FDA Category 1?

Key dates

The 12 peptides in the 2026 review

How to access Category 1 peptides legally

How compounding pharmacy quality differs from research vendors

Frequently asked questions

Related guides

FDA Category 1 Peptides 2026:
What the Reclassification Means